SCHEMBL9890786

SCHEMBL9890786

CNC(=O)Cc1cc(F)c(F)cc1-c1ccccc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.43
LMNA P02545 1/20 0.43
ADORA2A P29274 4/20 0.42
ADORA1 P30542 4/20 0.42
ADORA3 P0DMS8 3/20 0.42
ADORA2B P29275 1/20 0.42
PPIA P62937 1/20 0.40
GAA P10253 1/20 0.40
ALDH1A1 P00352 3/20 0.39
MAPT P10636 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
CXCL8 P10145 1/20 0.37
NPC1 O15118 1/20 0.36
PLK4 O00444 1/20 0.36
PDPK1 O15530 1/20 0.36
DAPK3 O43293 1/20 0.36
DYRK3 O43781 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2395314 0.86 RAB9A (0.49) RAB9ALMNAADORA2AADORA1ADORA3
SCHEMBL9890732 0.85 ALDH1A1 (0.43) RAB9ALMNAADORA2AADORA1ADORA3
SCHEMBL2395717 0.85 SMN1; SMN2 (0.43) RAB9ALMNAADORA2AADORA1ADORA3
SCHEMBL2395234 0.83 CNR1 (0.43) RAB9ALMNAALDH1A1MAPTMEN1
SCHEMBL9890678 0.81 CXCL8 (0.49) RAB9ALMNACXCL8SMN1; SMN2
SCHEMBL9890785 0.80 ALDH1A1 (0.41) RAB9ALMNAADORA2AADORA1ADORA3
SCHEMBL21776096 0.79 ALDH1A1 (0.56) RAB9ALMNAPPIAGAAALDH1A1
SCHEMBL9890787 0.78 SRC (0.41) RAB9ALMNAMEN1KMT2ASMN1; SMN2
SCHEMBL1177282 0.74 ALDH1A1 (0.53) RAB9ALMNAALDH1A1MAPTL3MBTL1
SCHEMBL9890748 0.72 CYP11B1 (0.46) KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 RAB9A 208/4885LMNA 3980/4885ADORA2A 2577/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 RAB9A 208/4885LMNA 3980/4885ADORA2A 2577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.